Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy (TFINE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01038661 |
Recruitment Status :
Completed
First Posted : December 24, 2009
Last Update Posted : February 28, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The Primary Objective is to evaluate the progression-free survival (PFS).
The secondary objectives are:
- To compare the disease control rates of different doses of Docetaxel+Cisplatin as first-line treatment according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria;
- To evaluate the overall response rate (ORR);
- To evaluate the time to disease progression (TTP);
- To evaluate the overall survival (OS);
- To evaluate the toxicity.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Neoplasms | Drug: Docetaxel Drug: Cisplatin Other: Best supportive care (BSC) | Phase 3 |
The study consists in:
- A first line treatment phase: participants receive 4 cycles of chemotherapy (each cycle contains 3 weeks) with either docetaxel (75 mg/m2) plus cisplatin (75 mg/m2) or docetaxel (60 mg/m2) plus cisplatin (75 mg/m2) ,
- A maintenance treatment phase: participants with disease control (complete response [CR], partial response [PR] or stable disease [SD]) after the initial treatment receive up to 6 cycles of chemotherapy with docetaxel (60 mg/m2) or best supportive care (BSC).
- A follow-up period from the end of study treatment until participant death or end of study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 375 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized, Controlled Study Comparing the Efficacy and Safety of Docetaxel (60mg/m2)Maintenance Treatment vs. Best Supportive Care Following First Line Chemotherapy With Different Doses of Docetaxel(75/60mg/m2)in Combination With Cisplatin in Patients With Local Advanced or Metastatic (Stage IIIB/IV)Non-Small Cell Lung Cancer |
Study Start Date : | November 2009 |
Actual Primary Completion Date : | August 2012 |
Actual Study Completion Date : | August 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²
Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
|
Drug: Docetaxel
Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-hour IV Other Name: Taxotere® Drug: Cisplatin Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-3-hour IV |
Experimental: First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²
Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
|
Drug: Docetaxel
Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-hour IV Other Name: Taxotere® Drug: Cisplatin Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-3-hour IV |
Experimental: Maintenance treatment: docetaxel (60 mg/m2)
Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
|
Drug: Docetaxel
Formulation: concentrated solution for intravenous infusion (IV) Route(s) of administration: 1-hour IV Other Name: Taxotere® |
Active Comparator: Maintenance treatment: best supportive care (BSC)
BSC until progressive disease
|
Other: Best supportive care (BSC)
Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator |
- Progression-free survival (PFS) during the maintenance treatment phase [ Time Frame: From 2nd randomization to progression or death of any cause (every 2 cycles (6 weeks) during study treatment, and then every 8 weeks during follow-up period) ]
- Disease control rate (DCR) during the first line treatment phase [ Time Frame: Every 2 cycles (6 weeks) ]
- Overall response rate (ORR) during the first line treatment phase [ Time Frame: Every 2 cycles (6 weeks) ]
- Time to disease progression (TTP) during the maintenance treatment phase [ Time Frame: From 2nd randomization up to disease progression (every 2 cycles (6 weeks)) ]
- Overall survival (OS) [ Time Frame: From 1st randomization to death of any cause (every 2 cycles (6 weeks) during study treatment, and then every 8 weeks during follow-up period) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Histologic or cytologic diagnosis of advanced non-small-cell lung cancer (NSCLC)
- Based on International Association for the Study of Lung Cancer (IASLC) 2009 new Tumor-Node-Metastasis (TNM) stage criteria of lung cancer, local advanced stage IIIB (not applicable for radical radiation therapy) disease or metastatic stage IV disease or recurrent disease
- At least one evaluable tumor lesion based on RECIST criteria (>= 20 mm with conventional techniques or >= 10 mm with spiral Computed Tomography scan)
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1
-
Adequate bone marrow reserve
- absolute neutrophil count >= 2.0×10^9/L
- platelets >= 100×10^9/L
- hemoglobin >= 9.0 g/dL
-
Adequate hepatic function
- total bilirubin <= Upper Normal Limit (UNL)
- Aspartate Amino Transferase (AST), Alanine Amino Transferase (ALT) <= 2.5 UNL
- alkaline phosphatase (ALP) <= 5 UNL
- Adequate renal function (serum creatinine <= UNL or creatinine clearance >= 60 mL/min)
- No prior chemotherapy was allowed or only (neo) adjuvant chemotherapy ended more than 6 months before treatment (patients should not have been heavily pre-treated, the maximum cumulative dose of cisplatin allowed is 350 mg/m²)
- Prior surgery was permitted only if the operation performed more than 4 weeks ago and the patient was completely recovery
- Childbearing potential either terminated or attenuated by the use of an approved contraceptive method
- Inform consent signed
Exclusion criteria:
- Other tumour type than advanced / metastatic NSCLC in recent 5 years (except cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous cell carcinoma of the skin).
- Presence of symptomatic central nervous system metastases
-
Inadequate liver function
- total bilirubin > 1 UNL
- ALT and/or AST>1.5 UNL associated with alkaline phosphatase > 2.5 UNL
- inadequate renal function (creatinine > 1.0 times UNL and in case of limit value, creatinine clearance < 60 mL/min)
- Prior radiation therapy, or surgery operation within 4 weeks
- Prior use of taxoids
- Active infection, or serious concomitant systemic disorder incompatible with the study
- Childbearing potential but unwilling to use of an approved contraceptive method
- Receive treatment from other clinical trials during this study treatment
- History of hypersensitivity to any of study medication
- Other serious concomitant abnormal or illness
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01038661
China | |
Sanofi-Aventis Administrative Office | |
Shanghai, China |
Study Director: | Clinical Sciences & Operations | Sanofi |
Responsible Party: | Sanofi |
ClinicalTrials.gov Identifier: | NCT01038661 |
Other Study ID Numbers: |
DOCET_L_04827 |
First Posted: | December 24, 2009 Key Record Dates |
Last Update Posted: | February 28, 2014 |
Last Verified: | February 2014 |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Docetaxel Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |